Last reviewed · How we verify
Resiquimod 0.03%
At a glance
| Generic name | Resiquimod 0.03% |
|---|---|
| Sponsor | Spirig Pharma Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) (PHASE1, PHASE2)
- Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Resiquimod 0.03% CI brief — competitive landscape report
- Resiquimod 0.03% updates RSS · CI watch RSS
- Spirig Pharma Ltd. portfolio CI